They are highly effective, but like blood pressure or lipid medications, if you stop taking them, the weight will creep back
(NIDDK) I also see a second misconception: that success on these medications is purely about eating less. In reality, the reason many patients do better with GLP-1-based treatment is that these medications can change the biology driving overeating, poor fullness signaling, and dysregulated blood sugar
The discrepancies may be attributed to the limitations of BMI as a lone evaluator of metabolic disorders
Eligibility in India generally means a BMI of 2730 with a metabolic complication (such as PCOS, fatty liver, or prediabetes) or a BMI above 30, alongside uncontrolled Type 2 diabetes, abdominal obesity, or strong family history of metabolic disease